卡介苗在临床上已试用于黑色素瘤、乳腺癌或肉瘤的皮肤转移等,近年来尚认为该药可治疗浅表性膀胱癌。1976年Morales等率先报道采用卡介苗治疗9例膀胱肿瘤,随防4个月,复发率仅11％,而通常复发率在61～90％,引起了有关专家们的研究兴趣。国内外大量的研究表明,卡介苗可限制膀胱原位癌生长,甚至可使其消失, BCG has been clinically tested for skin metastases in melanoma, breast cancer, or sarcoma. In recent years, it has been considered that the drug can treat superficial bladder cancer. In 1976, Morales et al. first reported the use of BCG in the treatment of 9 cases of bladder tumors. After 4 months of follow-up, the recurrence rate was only 11%, and the recurrence rate was usually 61 to 90%, which aroused the interest of relevant experts. A large number of studies at home and abroad have shown that BCG can limit the growth of bladder cancer in situ, and even make it disappear.